Capitolis Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Capitolis Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-181,600	Closed	-$11.3M	–	192
2021 Q4	$11.3M	Buy	181,600 +28,097	+18%	+$1.65M	0.07%	203
2021 Q3	$8.74M	Hold	153,503	–	–	0.08%	188
2021 Q2	$10.3M	Sell	153,503 -274,433	-64%	-$17.9M	0.12%	164
2021 Q1	$27M	Buy	427,936 +143,118	+50%	+$8.9M	0.47%	52
2020 Q4	$17.7M	Buy	+284,818	New	+$17.5M	0.3%	84

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capitolis Advisors's BMY Position: Q1 2022 in Review

Capitolis Advisors sold out of Bristol-Myers Squibb (BMY) in Q1 2022, closing a stake of 181,600 shares — an estimated $11.3M sold.

Capitolis Advisors first reported a position in BMY in Q4 2020 and held it in 5 quarters. The position peaked at $27M in Q1 2021. 2,515 funds tracked by Wall St. Rank hold BMY as of Q1 2022.

Capitolis Advisors reported no remaining Bristol-Myers Squibb position as of Q1 2022 after selling out during the quarter.
Capitolis Advisors sold 181,600 Bristol-Myers Squibb shares in Q1 2022, an estimated $11.3M.
Capitolis Advisors first reported a position in Bristol-Myers Squibb in Q4 2020 and held it in 5 quarters.
Capitolis Advisors's Bristol-Myers Squibb position peaked at $27M in Q1 2021.
2,515 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2022.

Based on Capitolis Advisors's 13F filing for Q1 2022, filed 12 May 2022.